Skip to main content

Table 1 Patient characteristics

From: Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study

  

Eribulin

(n = 91)

Capecitabine

(n = 79)

p

Age in years, n (%)

Median (range)

56 (30–76)

59 (36–74)

-

≥60

34 (37)

35 (44)

0.43

<60

57 (63)

44 (56)

Sex, n (%)

Male

0 (0)

0 (0)

-

Female

91 (100)

79 (100)

ECOG-PS, n (%)

0

55 (60)

43 (54)

0.44

1

36 (40)

35 (44)

2

0 (0)

1 (1)

HR, n (%)

Positive

71 (78)

70 (89)

0.1

Negative

20 (22)

9 (11)

ER, n (%)

Positive

68 (75)

65 (82)

0.27

Negative

23 (25)

14 (18)

PgR, n (%)

Positive

55 (60)

52 (66)

0.42

Negative

36 (40)

25 (32)

NA

0 (0)

2 (3)

-

HER2, n (%)

Positive

5 (6)

2 (3)

0.45

Negative

85 (93)

75 (95)

NA

1 (1)

2 (3)

-

Triple-negative, n (%)

17 (19)

9 (11)

0.21

Surgical history, n (%)

Positive

83 (91)

72 (91)

1.0

Negative

8 (9)

7 (9)

Neoadjuvant/adjuvant

chemotherapy, n (%)

Positive

76 (84)

63 (80)

0.56

Negative

15 (16)

16 (20)

Previous hormone therapy, n (%)

Positive

63 (69)

72 (91)

0.001

Negative

28 (31)

7 (9)

Previous anthracycline,

n (%)

Positive

85 (93)

67 (85)

0.08

Negative

6 (7)

12 (15)

Previous taxane, n (%)

Positive

88 (97)

73 (92)

0.31

Negative

3 (3)

6 (8)

Previous chemotherapy regimens, n (%)

0

11 (12)

18 (23)

0.001

1

29 (32)

39 (49)

2

51 (56)

22 (28)

Response, n (%)

PR

14 (15)

16 (20)

0.018

SD

43 (47)

49 (62)

PD

34 (37)

14 (18)

Albumin, n (%)

≥4.1 g/dL

55 (60)

51 (65)

0.64

<4.1 g/dL

36 (40)

28 (35)

LDH, n (%)

<222 U/L

38 (42)

48 (61)

0.01

≥222 U/L

53 (58)

31 (39)

CRP, n (%)

<0.15 mg/dL

39 (43)

46 (58)

0.06

≥0.15 mg/dL

52 (57)

33 (42)

NLR, n (%)

<3

65 (71)

56 (71)

1.0

≥3

26 (29)

23 (29)

ALC, n (%)

≥1,500/µL

31 (34)

36 (46)

0.16

<1,500/µL

60 (66)

43 (54)

LMR, n (%)

≥5

36 (40)

45 (57)

0.03

<5

55 (60)

34 (43)

PLR, n (%)

<250

73 (80)

68 (86)

0.41

≥250

18 (20)

11 (14)

  1. ALC absolute lymphocyte count; CRP C-reactive protein; ECOG-PS Eastern Cooperative Oncology Group-performance status; ER oestrogen receptor; HER2 human epidermal growth factor receptor 2; HR hormone receptor; LDH lactate dehydrogenase; LMR lymphocyte-to-monocyte ratio; NA not available; NLR neutrophil-to-lymphocyte ratio; PD progressive disease; PgR progesterone receptor; PLR platelet-to-lymphocyte ratio; PR partial response; SD stable disease